Catalent: Difference between revisions
Citation bot (talk | contribs) Removed parameters. | Use this bot. Report bugs. | #UCB_CommandLine |
Citation bot (talk | contribs) Removed parameters. | Use this bot. Report bugs. | #UCB_CommandLine |
||
Line 49: | Line 49: | ||
In November 2014, Catalent announced it had acquired Micron Technologies, a provider of particle size engineering technologies.<ref name=":0" /> The acquisition allowed Catalent to expand its portfolio of drug delivery technologies.<ref name=":0">{{Cite web|url=http://www.pharmtech.com/catalent-acquires-micron-technologies-adds-particle-engineering-capabilities-portfolio|title=Catalent Acquires Micron Technologies, Adds Particle Engineering Capabilities to Portfolio|website=Pharmtech|date=13 November 2014 }}</ref> |
In November 2014, Catalent announced it had acquired Micron Technologies, a provider of particle size engineering technologies.<ref name=":0" /> The acquisition allowed Catalent to expand its portfolio of drug delivery technologies.<ref name=":0">{{Cite web|url=http://www.pharmtech.com/catalent-acquires-micron-technologies-adds-particle-engineering-capabilities-portfolio|title=Catalent Acquires Micron Technologies, Adds Particle Engineering Capabilities to Portfolio|website=Pharmtech|date=13 November 2014 }}</ref> |
||
In 2016, Catalent licensed the anti-body drug conjugate (ADC) to Triphase Accelerator to help with [[oncology]] development,<ref>{{Cite web|url=https://www.biopharmadive.com/news/catalent-out-licenses-adc-to-triphase/427780/|title=Catalent out-licenses ADC to Triphase|website=BioPharma Dive|language=en-US|access-date=2019-10-04}}</ref> and bought Pharmatek Laboratories to add spray drying to their manufacturing capabilities.<ref>{{Cite news|url=https://investingnews.com/daily/life-science-investing/pharmaceutical-investing/catalent-buys-pharmatek-spray-drying-technology/|title=Catalent Buys Pharmatek and Lands Spray Drying Technology|date=14 September 2016|work=Pharmaceutical Investing News |
In 2016, Catalent licensed the anti-body drug conjugate (ADC) to Triphase Accelerator to help with [[oncology]] development,<ref>{{Cite web|url=https://www.biopharmadive.com/news/catalent-out-licenses-adc-to-triphase/427780/|title=Catalent out-licenses ADC to Triphase|website=BioPharma Dive|language=en-US|access-date=2019-10-04}}</ref> and bought Pharmatek Laboratories to add spray drying to their manufacturing capabilities.<ref>{{Cite news|url=https://investingnews.com/daily/life-science-investing/pharmaceutical-investing/catalent-buys-pharmatek-spray-drying-technology/|title=Catalent Buys Pharmatek and Lands Spray Drying Technology|date=14 September 2016|work=Pharmaceutical Investing News}}</ref> In September 2017, Catalent agreed to acquire Cook Pharmica for $950 million, allowing Catalent to expand their biologic manufacturing.<ref>{{Cite web|url=https://pharmaceuticalcommerce.com/latest-news/catalent-targets-biologics-cook-pharmica-acquisition/|title=Catalent targets biologics with Cook Pharmica acquisition|date=2017-09-19|website=Pharmaceutical Commerce|language=en-US|access-date=2019-11-21}}</ref> In July 2018, Catalent extended their work with Juniper Pharmaceuticals with a $133 million deal.<ref>{{Cite news|url=https://www.fiercepharma.com/manufacturing/catalent-extends-expansion-130m-deal-for-juniper-pharmaceuticals|title=Catalent extends expansion with $133M deal for Juniper Pharmaceuticals|newspaper=Fierce Pharma|date=3 July 2018|language=en|access-date=2019-08-16}}</ref> |
||
Alessandro Maselli was appointed as president and chief operating officer in 2019, a newly created position within Catalent.<ref>{{Cite web|url=https://finance.yahoo.com/news/catalent-names-alessandro-maselli-president-120000487.html|title=Catalent Names Alessandro Maselli President and Chief Operating Officer|website=finance.yahoo.com|language=en-US|access-date=2019-02-19}}</ref> In March, 2019, Catalent invested more than $27 million to commercialize Zydis Ultra. The investment includes new [[Zydis]] lines; changes to one of their facilities in [[Swindon]], UK; and a custom suite for commercial equipment.<ref>{{Cite web|url=http://www.pharmtech.com/catalent-invests-zydis-ultra-commercialization|title=Catalent Invests in Zydis Ultra Commercialization|website=pharmtech.com|date=20 March 2019 }}</ref> Later in 2019, Catalent partnered with GB Sciences to develop a cannabinoid-derived medicine for Parkinson's disease utilizing the Zydis delivery method.<ref>{{Cite web|url=https://mjbizmagazine.com/wellness-products-take-off-in-the-growing-recreational-cannabis-market/|title=Wellness products take off in the growing recreational cannabis market|date=2019-10-01|website=Marijuana Business Magazine|language=en-US|access-date=2019-12-09}}</ref> |
Alessandro Maselli was appointed as president and chief operating officer in 2019, a newly created position within Catalent.<ref>{{Cite web|url=https://finance.yahoo.com/news/catalent-names-alessandro-maselli-president-120000487.html|title=Catalent Names Alessandro Maselli President and Chief Operating Officer|website=finance.yahoo.com|language=en-US|access-date=2019-02-19}}</ref> In March, 2019, Catalent invested more than $27 million to commercialize Zydis Ultra. The investment includes new [[Zydis]] lines; changes to one of their facilities in [[Swindon]], UK; and a custom suite for commercial equipment.<ref>{{Cite web|url=http://www.pharmtech.com/catalent-invests-zydis-ultra-commercialization|title=Catalent Invests in Zydis Ultra Commercialization|website=pharmtech.com|date=20 March 2019 }}</ref> Later in 2019, Catalent partnered with GB Sciences to develop a cannabinoid-derived medicine for Parkinson's disease utilizing the Zydis delivery method.<ref>{{Cite web|url=https://mjbizmagazine.com/wellness-products-take-off-in-the-growing-recreational-cannabis-market/|title=Wellness products take off in the growing recreational cannabis market|date=2019-10-01|website=Marijuana Business Magazine|language=en-US|access-date=2019-12-09}}</ref> |
||
Line 58: | Line 58: | ||
=== 2020-present === |
=== 2020-present === |
||
In January 2020, Catalent purchased a manufacturing facility located in [[Anagni]], Italy, from [[Bristol-Myers Squibb]], to manufacture and package biologic and oral solid dose products for multiple companies.<ref>{{Cite news|url=https://www.outsourcing-pharma.com/Article/2020/01/13/Bristol-Myers-offloads-manufacturing-plant-to-Catalent|title=Bristol-Myers offloads manufacturing plant to Catalent|date=13 January 2020|work=Outsourcing-Pharma |
In January 2020, Catalent purchased a manufacturing facility located in [[Anagni]], Italy, from [[Bristol-Myers Squibb]], to manufacture and package biologic and oral solid dose products for multiple companies.<ref>{{Cite news|url=https://www.outsourcing-pharma.com/Article/2020/01/13/Bristol-Myers-offloads-manufacturing-plant-to-Catalent|title=Bristol-Myers offloads manufacturing plant to Catalent|date=13 January 2020|work=Outsourcing-Pharma}}</ref> In February 2020, Catalent agreed to acquire MaSTherCell, a Belgian gene and cell therapy manufacturer, for $315 million. The acquisition allows Catalent to expand into cell therapy development.<ref>{{Cite news|url=https://www.fiercepharma.com/manufacturing/catalent-laying-out-315m-to-snatch-another-gene-therapy-cdmo|title=Catalent laying out $315M to snatch another gene therapy CDMO|work=FiercePharma|access-date=3 February 2020}}</ref><ref>{{Cite news|url=https://www.manufacturingchemist.com/news/article_page/Catalent_adds_to_regenerative_therapy_portfolio_with_315m_acquisition/162009|title=Catalent adds to regenerative therapy portfolio with $315m acquisition|date=3 February 2020|work=Manufacturing Chemist}}</ref> |
||
In 2020, Catalent partnered with multiple drugmakers, including [[Pfizer]], [[Johnson & Johnson]],<ref>{{Cite web|date=2020-05-09|title=Pfizer to outsource some drug production, focus on coronavirus vaccine|url=https://www.cnbc.com/2020/05/08/pfizer-to-outsource-some-drug-production-focus-on-coronavirus-vaccine.html|access-date=2020-06-16|website=CNBC|language=en}}</ref> [[AstraZeneca]],<ref>{{Cite news|date=2020-06-15|title=AstraZeneca Picks Catalent for Packaging, Supplying Potential COVID-19 Vaccine|language=en-US|work=The New York Times|url=https://www.nytimes.com/reuters/2020/06/15/us/15reuters-health-coronavirus-astrazeneca-catalent.html |
In 2020, Catalent partnered with multiple drugmakers, including [[Pfizer]], [[Johnson & Johnson]],<ref>{{Cite web|date=2020-05-09|title=Pfizer to outsource some drug production, focus on coronavirus vaccine|url=https://www.cnbc.com/2020/05/08/pfizer-to-outsource-some-drug-production-focus-on-coronavirus-vaccine.html|access-date=2020-06-16|website=CNBC|language=en}}</ref> [[AstraZeneca]],<ref>{{Cite news|date=2020-06-15|title=AstraZeneca Picks Catalent for Packaging, Supplying Potential COVID-19 Vaccine|language=en-US|work=The New York Times|url=https://www.nytimes.com/reuters/2020/06/15/us/15reuters-health-coronavirus-astrazeneca-catalent.html|access-date=2020-06-16}}</ref> and [[Moderna]]<ref>{{Cite web|title=Moderna Is the Latest Coronavirus Vaccine Partner for Catalent|url=https://www.barrons.com/articles/moderna-coronavirus-vaccine-partner-catalent-production-51593099741|url-status=live|access-date=2020-07-07|website=Barrons|language=en-US|archive-url=https://web.archive.org/web/20200625155958/https://www.barrons.com/articles/moderna-coronavirus-vaccine-partner-catalent-production-51593099741 |archive-date=25 June 2020 }}</ref> to provide manufacturing, vial filling and packaging capabilities for COVID-19 vaccine candidates.<ref>{{Cite news|date=2020-05-27|title='Vaccine Nationalism': A New Dynamic in the Race to Quash Coronavirus|language=en-US|work=The Wall Street Journal|url=https://www.wsj.com/articles/geopolitical-power-play-over-coronavirus-vaccine-leaves-drugmakers-in-the-middle-11590577849|access-date=2020-06-16}}</ref><ref>{{Cite news|date=2020-06-25|title=Vaccine makers face biggest medical manufacturing challenge in history|language=en|work=Reuters|url=https://www.reuters.com/article/us-health-coronavirus-vaccines-manufactu-idUSKBN23W1ND}}</ref> In the partnership with AstraZeneca, Catalent will provide manufacturing from its Maryland facility and vial filling and packaging from its Italian facility.<ref>{{Cite web|date=26 August 2020|title=AstraZeneca taps Catalent Inc. to manufacture Covid-19 vaccine candidate in Maryland|url=https://www.bizjournals.com/baltimore/news/2020/08/26/catalent-to-manufacture-covid-19-vaccine-in-md.html|access-date=2020-09-24|website=Baltimore Business Journal}}</ref> Catalent also partnered with ViralClear to manufacture a COVID-19 treatment candidate at Catalent's [[St. Petersburg, Florida|St. Petersburg]] facility.<ref>{{Cite web|title=Manufacturer to help develop potential Covid treatment at St. Pete facility|url=https://www.bizjournals.com/tampabay/news/2020/06/23/why-this-medical-company-partnered-with-a-st-pete.html|access-date=2020-07-17|website=Tampa Bay Business Journal}}</ref> Also in 2021, Catalent acquired German gene therapy development firm Rheincell Therapeutics.<ref>{{Cite web|date=6 August 2021|title=Catalent Finalizes RheinCell Therapeutics Acquisition|url=https://www.biopharminternational.com/view/catalent-finalizes-rheincell-therapeutics-acquisition|url-status=live|website=BioPharm International|archive-url=https://web.archive.org/web/20210809213536/https://www.biopharminternational.com/view/catalent-finalizes-rheincell-therapeutics-acquisition |archive-date=9 August 2021 }}</ref> |
||
In August 2021, Catalent announced plans to acquire nutritional supplement company [[Bettera Holdings]] LLC for $1 billion. The deal will allow Catalent to manufacture vitamins, minerals and supplements in gummy form.<ref>{{Cite news|last=Hopkins|first=Jared S.|date=2021-08-30|title=WSJ News Exclusive {{!}} Catalent to Buy Supplement Maker Bettera Holdings for $1 Billion|language=en-US|work=Wall Street Journal|url=https://www.wsj.com/articles/catalent-to-buy-supplement-maker-bettera-holdings-for-1-billion-11630274401|access-date=2021-08-30|issn=0099-9660}}</ref> |
In August 2021, Catalent announced plans to acquire nutritional supplement company [[Bettera Holdings]] LLC for $1 billion. The deal will allow Catalent to manufacture vitamins, minerals and supplements in gummy form.<ref>{{Cite news|last=Hopkins|first=Jared S.|date=2021-08-30|title=WSJ News Exclusive {{!}} Catalent to Buy Supplement Maker Bettera Holdings for $1 Billion|language=en-US|work=Wall Street Journal|url=https://www.wsj.com/articles/catalent-to-buy-supplement-maker-bettera-holdings-for-1-billion-11630274401|access-date=2021-08-30|issn=0099-9660}}</ref> |
Revision as of 18:24, 27 September 2023
This article may have been created or edited in return for undisclosed payments, a violation of Wikipedia's terms of use. It may require cleanup to comply with Wikipedia's content policies, particularly neutral point of view. (January 2022) |
Company type | Public company |
---|---|
Industry | Pharmaceuticals |
Predecessor | Cardinal Health PTS |
Founded | 2007 |
Headquarters | Somerset, New Jersey, U.S. |
Number of locations | 49 (2020)[1] |
Key people | Alessandro Maselli (President, CEO & Director), Matti Masanovich (CFO) |
Services | Drug pre-formulation, formulation, analytical testing, clinical and commercial manufacturing, clinical packaging and supply chain, regulatory consulting |
Revenue | US$4.828 Billion (Fiscal Year Ended June 30, 2022)[2] |
US$0.756 Billion (Fiscal Year Ended June 30, 2022)[2] | |
US$0.519 Billion (Fiscal Year Ended June 30, 2022)[2] | |
Total assets | US$10.507 Billion (Fiscal Year Ended June 30, 2022)[2] |
Total equity | US$4.795 Billion (Fiscal Year Ended June 30, 2022)[2] |
Number of employees | 14,000 (2020) |
Website | catalent |
Catalent, Inc. (Catalent Pharma Solutions) is a multinational corporation headquartered in Somerset, New Jersey. It is a global provider of delivery technologies, development, drug manufacturing, biologics, gene therapies and consumer health products. It employs more than 14,000 people,[3] including approximately 2,400 scientists and technicians. In fiscal year 2020, it generated over $3 billion in annual revenue.[1]
Catalent was formed in April 2007 when affiliates of the Blackstone Group L.P. acquired the core of the pharmaceutical technologies and services (PTS) segment of Cardinal Health, Inc.[4] Cardinal Health created PTS through a series of acquisitions starting with R.P. Scherer Corporation in 1998.[5]
In 2014, Catalent became a public company, listed on the New York Stock Exchange.
History
Before 2007
In 1996, Cardinal Health acquired PCI (Headquarters: Philadelphia, Pennsylvania).[6] PCI (Packaging Coordinators Inc.) is a pharmaceutical contract packing service for commercial and clinical packaging.[7]
In 1998, Cardinal Health acquired R.P. Scherer Corporation (Headquarters: Troy, Michigan).[8] Robert Pauli Scherer founded the R.P. Scherer Corporation to commercialize his innovation of softgel encapsulation using the rotary die production process.[9] The following year, in 1999, Cardinal Health acquired Automatic Liquid Packaging, Inc. (Headquarters: Woodstock, Ill.),[6] whose Blow-Fill-Seal Technology allowed Cardinal to enter the sterile product market.[9]
In 2001, Cardinal Health acquired International Processing Corporation, a company that was renowned for its expertise in oral modified-release dosage form development and manufacturing. In 2002, Cardinal Health acquired Magellan Laboratories Inc., a company that specialized in product development expertise.[6] In 2003, Cardinal Health acquired Gala Biotech (Headquarters: Madison, Wisconsin).[6] In the same year, Cardinal Health also acquired Intercare Group PLC, broadening its global capabilities in Europe.[6]
From 2004 to 2006, Cardinal Health further expanded its reach in biotechnology and pharmaceutical markets through multiple acquisitions.[6]
Formation of Catalent in 2007
In 2007, the pharmaceutical technologies and services segment of Cardinal Health was purchased by Blackstone Group and re-branded as Catalent Pharma Solutions.[4]
After 2007 and initial public offering-2019
In 2012, Catalent acquired Aptuit, a clinical supply company. As part of the deal, Catalent gained three sites in the US, two in the UK, and one in Singapore.[10] Catalent also acquired all remaining shares for the R.P Scherer site in Eberbach, Germany.[8][11][12] In 2013, Catalent continued the global expansion of its Softgel capabilities through a joint venture with Zhejiang Jaing Yuan Tang Biotechnology Co, a China-based company, and Relthy Laboratories in Brazil.[13]
Catalent announced its initial public offering in July 2014. After raising more than $870 million, Catalent became a publicly traded company on the New York Stock Exchange (NYSE).[14] The company priced its 42.5 million shares of common stock at $20.50 apiece, with a market capitalization of $2.4 billion. The shares began trading on the NYSE on 31 July 2014, under the ticker symbol CTLT.[14]
In November 2014, Catalent announced it had acquired Micron Technologies, a provider of particle size engineering technologies.[15] The acquisition allowed Catalent to expand its portfolio of drug delivery technologies.[15]
In 2016, Catalent licensed the anti-body drug conjugate (ADC) to Triphase Accelerator to help with oncology development,[16] and bought Pharmatek Laboratories to add spray drying to their manufacturing capabilities.[17] In September 2017, Catalent agreed to acquire Cook Pharmica for $950 million, allowing Catalent to expand their biologic manufacturing.[18] In July 2018, Catalent extended their work with Juniper Pharmaceuticals with a $133 million deal.[19]
Alessandro Maselli was appointed as president and chief operating officer in 2019, a newly created position within Catalent.[20] In March, 2019, Catalent invested more than $27 million to commercialize Zydis Ultra. The investment includes new Zydis lines; changes to one of their facilities in Swindon, UK; and a custom suite for commercial equipment.[21] Later in 2019, Catalent partnered with GB Sciences to develop a cannabinoid-derived medicine for Parkinson's disease utilizing the Zydis delivery method.[22]
In April 2019, Catalent agreed to acquire Paragon Bioservices Inc for $1.2 billion to expand its gene-therapy manufacturing capabilities.[23] The deal was completed in May 2019 and included an agreement with Sarepta Therapeutics, a gene therapy manufacturer.[24] As of October 2019, Paragon's employee numbers have almost doubled since the April acquisition.[25]
In June 2019, Catalent acquired Bristol-Myers' European launch pad to expand its global CDMO.[26]
2020-present
In January 2020, Catalent purchased a manufacturing facility located in Anagni, Italy, from Bristol-Myers Squibb, to manufacture and package biologic and oral solid dose products for multiple companies.[27] In February 2020, Catalent agreed to acquire MaSTherCell, a Belgian gene and cell therapy manufacturer, for $315 million. The acquisition allows Catalent to expand into cell therapy development.[28][29]
In 2020, Catalent partnered with multiple drugmakers, including Pfizer, Johnson & Johnson,[30] AstraZeneca,[31] and Moderna[32] to provide manufacturing, vial filling and packaging capabilities for COVID-19 vaccine candidates.[33][34] In the partnership with AstraZeneca, Catalent will provide manufacturing from its Maryland facility and vial filling and packaging from its Italian facility.[35] Catalent also partnered with ViralClear to manufacture a COVID-19 treatment candidate at Catalent's St. Petersburg facility.[36] Also in 2021, Catalent acquired German gene therapy development firm Rheincell Therapeutics.[37]
In August 2021, Catalent announced plans to acquire nutritional supplement company Bettera Holdings LLC for $1 billion. The deal will allow Catalent to manufacture vitamins, minerals and supplements in gummy form.[38]
In October 2021, Catalent opened a 6,000 square-meter clinical supply facility in Shiga, Japan.[39]
In October 2022, Catalent announced a $12M expansion at a Kansas City, MO facility.[40]
January 2023, Catalent partnered with Sarepta Therapeutics to manufacture delandistrogene moxeparvovec (SRP-9001). Sarepta's most advanced gene therapy candidate for the treatment of Duchenne muscular dystrophy (DMD).[41][42][43]
Financials
# | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|---|
Sales/Revenue | 1.85B | 2.08B | 2.46B | 2.52B | 3.09B | 3.998B | 4.828B |
Total Current Assets | 3.09B | 2.45B | 4.53B | 6.18B | 7.78B | 9.112B | 10.507B |
Net Operating Cash Flow | 155.3M | 299.5M | 374.5M | 247.7M | 440.3M | 0.585B | 0.519B |
References
- ^ a b c "Catalent 2022 Annual Report" (PDF). Catalent Investors. Retrieved 5 June 2023.
- ^ a b c d e "Catalent, Inc. 2020 Annual Report" (PDF). s23.q4cdn.com. 30 June 2021. Retrieved 10 October 2021.
- ^ "Catalent Boosts Supply Chain Transparency in Response to COVID-19 Manufacturing Urgency". BioSpace. Archived from the original on 1 November 2020. Retrieved 8 November 2020.
- ^ a b "Cardinal Health Completes Sale of Pharmaceutical Technologies and Services Segment to The Blackstone Group". Dublin, Ohio: Blackstone Group. 10 April 2007.
- ^ "Cardinal Health Agrees to Acquire Scherer for $2.07 Billion in Stock". The Wall Street Journal. 19 May 1998. Retrieved 2 December 2019.
- ^ a b c d e f "Cardinal Health's timeline -- CardinalHealth.com". CardinalHealth.com. Archived from the original on 11 April 2015. Retrieved 7 April 2015.
- ^ "PCI leads the market in healthcare packaging solutions". PCI Services. Retrieved 7 April 2015.
- ^ a b "Catalent completes acquisition of R P Scherer Eberbach". Manufacturing Chemist. 1 March 2012. Retrieved 7 April 2015.
- ^ a b Kuehn, Steven (6 October 2014). "Container Innovation's Prairie Home". Pharmaceutical Manufacturing. Retrieved 7 April 2015.
- ^ "Catalent completes Aptuit deal". BioPharma-reporter.com. 20 February 2012. Retrieved 7 April 2015.
- ^ Wasserman, Robert (8 September 2016). "2 big companies and 1 small one to target in the pharma/biotech space". TheStreet. Retrieved 9 July 2019.
- ^ "Gelita and R.P. Scherer End 60 Year Joint Venture". .foodingredientsfirst.com/. Retrieved 9 July 2019.
- ^ Stanton, Dan (10 October 2013). "Catalent's Brazilian acquisition supports global softgel strategy". inPharma-technologist.com. Retrieved 7 April 2015.
- ^ a b "Catalent Issues Initial Public Offering". No. 8. PharmTech.com. Pharmaceutical Technology Sourcing and Management. 4 August 2014. Retrieved 7 April 2015.
- ^ a b "Catalent Acquires Micron Technologies, Adds Particle Engineering Capabilities to Portfolio". Pharmtech. 13 November 2014.
- ^ "Catalent out-licenses ADC to Triphase". BioPharma Dive. Retrieved 4 October 2019.
- ^ "Catalent Buys Pharmatek and Lands Spray Drying Technology". Pharmaceutical Investing News. 14 September 2016.
- ^ "Catalent targets biologics with Cook Pharmica acquisition". Pharmaceutical Commerce. 19 September 2017. Retrieved 21 November 2019.
- ^ "Catalent extends expansion with $133M deal for Juniper Pharmaceuticals". Fierce Pharma. 3 July 2018. Retrieved 16 August 2019.
- ^ "Catalent Names Alessandro Maselli President and Chief Operating Officer". finance.yahoo.com. Retrieved 19 February 2019.
- ^ "Catalent Invests in Zydis Ultra Commercialization". pharmtech.com. 20 March 2019.
- ^ "Wellness products take off in the growing recreational cannabis market". Marijuana Business Magazine. 1 October 2019. Retrieved 9 December 2019.
- ^ Hopkins, Kimberly Chin and Jared S. (15 April 2019). "Catalent to Buy Paragon Bioservices for $1.2 Billion". Wall Street Journal. Retrieved 1 November 2019.
- ^ "Catalent's new prize, Paragon, adding capacity to make Sarepta gene therapies". Fierce Pharma. 21 May 2019. Retrieved 26 November 2019.
- ^ "Paragon growing quickly toward 1,000 employees after Catalent acquisition". Baltimore Business Journal. 17 October 2019. Archived from the original on 29 October 2020. Retrieved 23 December 2019.
- ^ "'It's a growth play': Catalent acquires Bristol-Myers' European launch pad, expanding global CDMO ops". Endpoints News. Retrieved 18 October 2019.
- ^ "Bristol-Myers offloads manufacturing plant to Catalent". Outsourcing-Pharma. 13 January 2020.
- ^ "Catalent laying out $315M to snatch another gene therapy CDMO". FiercePharma. Retrieved 3 February 2020.
- ^ "Catalent adds to regenerative therapy portfolio with $315m acquisition". Manufacturing Chemist. 3 February 2020.
- ^ "Pfizer to outsource some drug production, focus on coronavirus vaccine". CNBC. 9 May 2020. Retrieved 16 June 2020.
- ^ "AstraZeneca Picks Catalent for Packaging, Supplying Potential COVID-19 Vaccine". The New York Times. 15 June 2020. Retrieved 16 June 2020.
- ^ "Moderna Is the Latest Coronavirus Vaccine Partner for Catalent". Barrons. Archived from the original on 25 June 2020. Retrieved 7 July 2020.
- ^ "'Vaccine Nationalism': A New Dynamic in the Race to Quash Coronavirus". The Wall Street Journal. 27 May 2020. Retrieved 16 June 2020.
- ^ "Vaccine makers face biggest medical manufacturing challenge in history". Reuters. 25 June 2020.
- ^ "AstraZeneca taps Catalent Inc. to manufacture Covid-19 vaccine candidate in Maryland". Baltimore Business Journal. 26 August 2020. Retrieved 24 September 2020.
- ^ "Manufacturer to help develop potential Covid treatment at St. Pete facility". Tampa Bay Business Journal. Retrieved 17 July 2020.
- ^ "Catalent Finalizes RheinCell Therapeutics Acquisition". BioPharm International. 6 August 2021. Archived from the original on 9 August 2021.
- ^ Hopkins, Jared S. (30 August 2021). "WSJ News Exclusive | Catalent to Buy Supplement Maker Bettera Holdings for $1 Billion". Wall Street Journal. ISSN 0099-9660. Retrieved 30 August 2021.
- ^ "Catalent's Momentum Continues with Up to 600 New Jobs Being Added". BioSpace. Retrieved 7 January 2022.
- ^ "Catalent Announces $12 Million Expansion Program at Kansas City Facility". Contract Pharma. Retrieved 2 December 2022.
- ^ Keenan, Joseph (5 January 2023). "Catalent inks deal to manufacture Sarepta's DMD gene therapy". Fierce Pharma. Retrieved 24 January 2023.
- ^ "Sarepta marches forward with its potential DMD gene therapy and an expanded Catalent manufacturing deal". Endpoints News. Retrieved 24 January 2023.
- ^ "Sarepta and Catalent Expand Strategic Manufacturing Partnership With Commercial Supply Agreement for Duchenne Muscular Dystrophy Gene Therapy Candidate". www.businesswire.com. 5 January 2023. Retrieved 24 January 2023.
External links
- Official website
- Business data for Catalent, Inc.:
- Companies based in Somerset County, New Jersey
- Pharmaceutical companies established in 2007
- Companies listed on the New York Stock Exchange
- Pharmaceutical companies based in New Jersey
- Gene therapy
- Biotechnology companies of the United States
- Multinational companies headquartered in the United States
- Life sciences industry
- Drug discovery companies
- Research and development in the United States
- 2014 initial public offerings